Research & Registry

Phase IV Studies

Post-Marketing (Phase IV) Safety Study of Canakinumab

Project Description/Overview

CARRA is working with Novartis to provide prospective observational data from the Registry about the safety of canakinumab for the treatment of systemic JIA.

Enrollment

This study began in 2015.

Why This Is Important

It is important to continue to collect information about the safety of medications after they are approved for use. Information about long-term safety and uncommon adverse events are especially important.


Project Name

Post-Marketing (Phase IV) Safety Study of Tocilizumab

Project Description/Overview

CARRA is working with Roche to provide prospective observational data from the Registry about the safety of tocilizumab for the treatment of polyarticular JIA.

Enrollment

This study began in 2016.

Why This Is Important

It is important to continue to collect information about the safety of medications after they are approved for use. Information about long-term safety and uncommon adverse events are especially important.